JP Morgan Downgrades Upstream Bio to 'Hold'
JP Morgan analyst Tessa Romero lowers Upstream Bio's rating to 'hold' with an $8 target, a 33% upside from the current price.
Key Points
- JP Morgan analyst Tessa Romero downgraded Upstream Bio to 'hold' with a target price of $8 on June 12, 2026.
- JP Morgan's $8 price target implies 33% upside from Upstream Bio, Inc.'s ($UPB) current $6.01 share price.
- Upstream Bio shares are trading at $6.10, with a market cap of about $332 million, amid a challenging biotech sector.
- Despite the downgrade, other analysts maintain positive views, with a consensus 'buy' rating and a mean target of $38.25.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
JP Morgan has lowered its rating on Upstream Bio, Inc. (NasdaqGS:UPB) to 'hold', setting a price target of $8. This update comes from analyst Tessa Romero on June 12, 2026. The stock is currently trading around $6.10, reflecting a cautious outlook in a volatile biotech market.
What Changed in JP Morgan's Upstream Bio Position
JP Morgan's analyst Tessa Romero has downgraded Upstream Bio to a 'hold' rating, with an $8 price target. This move indicates a more reserved stance on the company's near-term prospects.
Other Institutional Activity in Upstream Bio
FMR LLC increased its stake in Upstream Bio by 583,361 shares, now holding 8,101,563 shares valued at approximately $72.9 million. ORBIMED ADVISORS LLC maintained its position with 5,693,589 shares worth $51.2 million. BlackRock, Inc. added 26,185 shares, reaching a total of 3,370,689 shares valued at about $30.3 million. Decheng Capital LLC reduced its holdings by 418,210 shares, now owning 2,724,868 shares valued at $24.5 million.
Upstream Bio, Inc. Stock Down 10.1%
Shares of Upstream Bio (NasdaqGS:UPB) are trading near $6.10. The company has a market cap of approximately $332 million. It currently has no meaningful forward P/E ratio due to its lack of profitability, with a beta of -2.11. The stock's 52-week range spans from $5.85 to $33.68, with a 50-day moving average of $8.80 and a 200-day moving average of $17.82. Upstream Bio maintains a strong liquidity position with a current ratio of 23.14 and a quick ratio of 21.74, alongside a low debt-to-equity ratio of 0.37.
Recent Earnings
Upstream Bio reported revenue of $3.32 million with a significant growth rate of 82.7%. Despite this, the company has not achieved profitability, reflected in a net margin of 0% and a return on equity of -41.8%. The next earnings report is expected on August 5, 2026.
Insider Buying and Selling at Upstream Bio, Inc.
Several insiders, including Marcella Ruddy, Daniella Beckman, Harold Edward Fleming, Ronald Renaud Jr., Liam Ratcliffe, and Erez Chimovits, each purchased 17,096 shares on June 9, 2026. These transactions were not part of a pre-planned trading program.
Analysts Set New Price Targets
On June 12, 2026, JP Morgan downgraded Upstream Bio to a 'hold' with an $8 price target. Earlier, on June 3, 2026, HC Wainwright & Co. initiated coverage with a 'buy' rating and a $36 target. Mizuho maintained its 'buy' rating with a $50 target on May 14, 2026. The consensus among analysts is a 'buy', with an average target price of $38.25 across eight opinions.
About Upstream Bio
Upstream Bio, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing treatments for inflammatory diseases, particularly severe respiratory disorders. The company's lead product, verekitug, is in Phase 2 trials for severe asthma and chronic rhinosinusitis with nasal polyps and in Phase 1 for chronic obstructive pulmonary disease. Founded in 2021, Upstream Bio is led by CEO Dr. E. Rand Sutherland and employs around 75 people.
Bottom Line
JP Morgan's downgrade of Upstream Bio to 'hold' reflects a cautious approach amid market volatility. Despite this, the company has strong institutional backing and a positive consensus from other analysts. As always, 13F filings and analyst ratings are backward-looking and may not represent current positions or views.
Get Upstream Bio, Inc. alerts
New 13F filings, insider trades, and analyst moves on $UPB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.